Frondoside a suppressive effects on lung cancer survival, tumor growth, angiogenesis, invasion, and metastasis

Area of Science:

• Pharmacology
• Oncology
• Marine Natural Products

Background:

• Developing less toxic lung cancer therapeutics is crucial for improving patient survival.
• Frondoside A, a triterpenoid glycoside from Cucumaria frondosa, is a safe compound with potential anti-cancer properties.

Purpose of the Study:

• To investigate the efficacy of Frondoside A against lung cancer.
• To evaluate its effects on cancer cell survival, migration, invasion, tumor growth, metastasis, and angiogenesis, both alone and with cisplatin.

Main Methods:

• In vitro studies on various cancer cell lines (LNM35, A549, etc.) to assess viability, migration, and invasion.
• In vivo studies using LNM35 tumor xenografts in athymic mice to evaluate tumor growth, metastasis, and angiogenesis.
• Chick Chorioallantoic Membrane (CAM) assay for angiogenesis inhibition.
• Combination therapy with cisplatin.

Main Results:

• Frondoside A induced dose-dependent cancer cell death via caspase 3/7 pathway (IC50: 1.7-2.5 µM).
• It inhibited cell migration, invasion, and angiogenesis in vitro.
• In vivo, Frondoside A reduced tumor growth, angiogenesis, and lymph node metastasis without significant toxicity.
• It enhanced cisplatin's anti-tumor effects.

Conclusions:

• Frondoside A demonstrates significant anti-cancer activity against lung cancer models.
• It possesses anti-migratory, anti-invasive, and anti-angiogenic properties.
• Frondoside A is a promising therapeutic candidate for lung cancer, potentially in combination with chemotherapy.